Abstract: A robotic surgical system includes a robotic arm, a tool driver, and a surgical instrument. The robotic arm that includes a distal end. The tool driver is operatively coupled with the distal end of the robotic arm. The surgical instrument includes a uterine manipulator and a tool drive adapter. The uterine manipulator is configured to be inserted into a uterus of a patient. The tool drive adapter is configured to move from a non-engaged configuration to an engaged configuration. In the non-engaged configuration, the tool drive adapter is spaced a distance from the uterine manipulator. In the engaged configuration, the uterine manipulator and the tool drive adapter are engaged. The tool drive adapter is operatively coupled with the tool driver in the non-engaged and engaged configurations.

Abstract: The present invention provides a system and method for measuring an impedance of one or more target cells before and after an electroporation protocol has been applied to the one or more target cells. The result of the impedance measurement provides a feedback control that can be implemented during and/or after the electroporation protocol to customize the electrical treatment for a particular target cell or cellular tissue.

Abstract: The present disclosure relates to compounds suitable for the inhibition of protein arginine methyl-transferase (PRMT), in particular PRMT5. These compounds may be for use as therapeutic agents, in particular, agents for use in the treatment and/or prevention of proliferative diseases, such as cancer.

Abstract: The present invention relates to compounds of Formula (I) as defined herein, and salts, hydrates and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to the use of compounds of Formula (I) in the treatment or prevention of PRMT5-mediated disorders, such as cancer.

Abstract: The present invention relates to compounds of Formula (I) as defined herein, and salts, hydrates and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to the use of compounds of Formula (I) in the treatment or prevention of PRMT5-mediated disorders, such as cancer.

Abstract: The present disclosure relates to compounds suitable for the inhibition of protein arginine methyl-transferase (PRMT), in particular PRMT5. These compounds may be for use as therapeutic agents, in particular, agents for use in the treatment and/or prevention of proliferative diseases, such as cancer.

Abstract: Various arrangements for determining an atomization element of a nebulizer is dry are presented. The vibratable element of the nebulizer may be energized with an electrical signal that sweeps from a first frequency to a second frequency. While energizing the vibratable element of the nebulizer with the electrical signal that sweeps from the first frequency to the second frequency, a sequence of impedance values of the vibratable element of the nebulizer may be measured. The sequence of impedance values of the vibratable element of the nebulizer may be analyzed to determine if the atomization element of the nebulizer is wet or dry.

Abstract: A Kinetic Energy penetrator round is shown effective in neutralizing incoming air borne threat munitions such as rockets, artillery, or mortars for instance, without posing a threat in urban environments to harm bystanders on the ground. There are also no hazards or expense with this round of cleaning up unexploded ordnance, which might have occurred with other types of rounds due to unreliability of self destruct mechanisms. Shown herein is a kinetic energy penetrator for air defense that merely self destructs beyond its operational range into fragments that are not lethal to personnel on ground; no pyrotechnic or energetic materials means are used to activate this self destruct process. A full bore projectile structure is shown that is composed of plural axi-symmetric circular disks stacked on each other and tied by a shape memory metal wire of Nitinol. While operational as a joined group, the disks are a formidable round to kill an incoming air target.

Abstract: The invention relates to thiophene carboxamides of formula (I), wherein A, R1, R2, R3, n and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Abstract: The invention relates to thiophene carboxamides of formula (I), wherein A, R1, R2, R3, n and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Abstract: Novel 1,3-dialkyloxy-2-propanol and alkoxylates thereof may be prepared in good yield by a convenient process comprising adding epichlorohydrin to a stoichiometric excess of alcohol, wherein the ratio of alcohol:epichlorohydrin is at least about 3:1, preferably in the presence of a Group 1A metal hydroxide and a phase transfer catalyst. The result shows excellent selectivity of to the 1,3-substitution positions, and the alkyl chain may be saturated or unsaturated and may contain one or more heteroatoms. The alkoxylates may include repeating alkoxy units in the 2-position. The compositions are useful as surfactants, diluents, and the like.

Abstract: A loudspeaker comprises a region devoid of electroacoustic transducers and at least two groups of electroacoustic transducers at the periphery of the region. Each of the groups is configured to produce a different sound field representative of an audio signal and each of the groups comprise a different set of transducers. This allows a more compact loudspeaker to be provided because the transducers can be located around the periphery of a visual display screen. Sound quality is not compromised because groups of transducers forming a subset of the totality of transducers are used for each sound signal, thereby avoiding alias beams.

Abstract: Heterocyclic amides of formula (1) wherein: X is N or CH; R4 and R5 together are either —S—C(R6)?C(R7)— or —C(R7)?C(R6)—S—; R6 and R7 are independently selected from, for example hydrogen, halo and C1-4alkyl; A is phenylene or heteroarylene; n is 0, 1 or 2; R1 is selected from for example halo, nitro, cyano, hydroxy, carboxy; R2 is hydrogen, hydroxy or carboxy; R3 is selected from for example hydrogen, hydroxy, aryl, heterocyclyl and C1-4alkyl(optionally substituted by 1 or 2 R8 groups); R8 is selected from for example hydroxy, —COCOOR9, —C(O)N(R9)(R10), —NHC(O)R9, (R9)(R10)N— and —COOR9; R9 and R10 are selected from for example hydrogen, hydroxy, C1-4alkyl (optionally substituted by 1 or 2 R13); R13 is selected from hydroxy, halo, trihalomethyl and C1-4alkoxy; or a pharmaceutically acceptable salt or pro-drug thereof, possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity.

Abstract: The invention relates to thiophene carboxamides of formula (I), wherein A, R1, R2, R3, n and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Abstract: The invention relates to thiophene carboxanmides of formula (I), wherein A, R1, R2, R3, n and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Abstract: The invention relates to thiophene carboxamides of formula (I) wherein Ar, R1, R2, R3, R4, R5, m and n are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Abstract: The invention relates to thiophene carboxamides of formula (I), wherein A, R1, R2, R3, R4, R5 and X are as defined in the specification, processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.

Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Abstract: The invention is directed to physiologically active compounds of general formula (I):— and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Abstract: Heterocyclic amides of formula (1) wherein: R1 is independently selected from, for example, C1-6alkyl, C5-7cycloalkyl, C5-7cycloalkylC1-3alkyl, C1-6alkoxy, C5-7cycloalkoxy, C5-7cycloalkylC1-3alkoxy, heterocyclyl, heterocyclylC1-3alkyl, heterocyclyloxy or heterocyclylC1-3alkoxy, R2 is phenyl or heteroaryl; R3 is independently selected from hydrogen, halo, nitro, cyano, hydroxy, carboxy, carbamoyl, C1-4alkyl, C2-4alkenyl, C2-4alkyl, C1-4alkoxy, C1-4alkanoyl, fluoromethyl, difluoromethyl trifluoromethyl and trifluoromethoxy; or a pharmaceutically acceptable salt or pro-drug thereof; possess glycogen phosphorylase inhibitory activity and accordingly have value in the treatment of disease states associated with increased glycogen phosphorylase activity. Processes for the manufacture of said heterocyclic amide derivatives and pharmaceutical compositions containing them are described.